Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !
Treceți offline cu aplicația Player FM !
In conversation with... Bernardo Goulart
Manage episode 411557643 series 2409123
Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.
205 episoade
Manage episode 411557643 series 2409123
Content provided by The Lancet and The Lancet Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet and The Lancet Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.
205 episoade
Toate episoadele
×1 In conversation with... Yannick Romero 24:48
24:48
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
24:48Dr Yannick Romero (Union for International Cancer Control) discusses his Policy Review on the changing landscape of the national cancer control plans and his work with the international cancer control partnership.
1 In conversation with... M Saiful Huq and Mostafa Aziz Sumon 22:15
22:15
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
22:15Professor M Saiful Huq (Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, USA) and Dr Mostafa Aziz Sumon (Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh) discuss their Series on Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries.…
1 In conversation with... Steven Horwitz 15:07
15:07
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
15:07Dr Steven Horwitz (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a phase 1 study of valemetostat in relapsed or refractory non-Hodgkin lymphoma and a phase 2 study of valemetostat in relapsed or refractory peripheral T-cell lymphoma.
1 In conversation with... Zachary Zumsteg 17:21
17:21
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
17:21Dr Zachary Zumsteg (Cedars-Sinai Medical Center, Los Angeles, CA, USA) discusses his Review on the challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations.
1 In conversation with... May Abdel-Wahab and Andrew Scott 40:45
40:45
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
40:45May Abdel-Wahab (Division of Human Health, Department of Nuclear Science and Applications, International Atomic Energy Agency, Vienna, Austria) and Andrew Scott (Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia) discuss The Lancet Oncology Commission on Radiotherapy and Theranostics.…
1 In conversation with... Kanwal Raghav 13:22
13:22
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
13:22Dr Kanwal Raghav (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his Article entitled, ‘Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a randomised, multicentre, phase 2 trial’.…
1 In conversation with... Emmy Boerrigter 11:41
11:41
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
11:41Dr Emmy Boerrigter (Department of Pharmacy, Radboud University Medical Center, Netherlands) discusses her Review on dose selection of novel anticancer drugs: exposing the gap between selected and required doses.
1 In conversation with... Hisham Mehanna and Sue Yom 36:56
36:56
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
36:56Dr Hisham Mehanna (University of Birmingham, Birmingham, UK) and Dr Sue Yom (University of California, San Francisco, San Francisco, CA, USA) discuss their four-paper Series on Head and Neck Cancer Consensus Recommendations in diagnosis and clinical trial endpoints.
1 In conversation with... Garth Strohbehn and Katie Lichter 24:08
24:08
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
24:08Dr Garth Strohbehn (Veteran Affairs Center for Clinical Management Research, Ann Arbor, Michigan, USA) and Dr Katie Lichter (University of California, San Francisco, USA) discuss their papers on the environmental impact of cancer treatments and the public harms resulting from it.
1 In conversation with... James Shultz, Ana Patricia Ortiz, and Leticia Nogueira 35:05
35:05
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
35:05Dr James Shultz, (University of Miami Miller School of Medicine, Miami, USA), Dr Ana Patricia Ortiz (University of Puerto Rico, and University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico), and Dr Leticia Nogueira (American Cancer Society, Georgia, USA) discuss their Personal View entitled, ‘Protecting Caribbean patients diagnosed with cancer from compounding disasters.…
1 In conversation with... Bernardo Goulart 11:22
11:22
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
11:22Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic non-small-cell lung cancer.
1 In conversation with... Maria Kyrgiou 25:42
25:42
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
25:42In a special episode on International Women's Day 2024, we speak with Maria Kyrgiou (Imperial College London, London, UK) about her Essay on innovations and disparities in gynaecological cancer care.
1 In conversation with... Georgios Lyratzopoulos 34:43
34:43
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
34:43Dr Georgios Lyratzopoulos (University College London, London, UK) discusses his two papers from the International Cancer Benchmarking Partnership on the use of chemotherapy or radiotherapy in eight common cancers in Norway, the UK, Canada, and Australia.
1 In conversation with... Mike Sathekge 16:06
16:06
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
16:06Professor Mike Sathekge (Department of Nuclear Medicine, University of Pretoria, Pretoria, South Africa) discusses his Article entitled, ‘Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre retrospective study.’
1 In conversation with... Shankar Siva 13:53
13:53
Redare mai Târziu
Redare mai Târziu
Liste
Like
Plăcut
13:53Senior Editor Owen Stretton talks to Professor Shankar Siva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery’s new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.
Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.